DTP cells are thought to have the potency to survive in the presence of inhibitors by escaping cell death induction and adapting to inhibitors and evolve into full-acquired resistance cells in a genetic or nongenetic manner in several cancers, including NSCLC with epidermal growth factor receptor (EGFR) mutation22–24. The gene discussed is EGFR; the disease is cancer.